ProMIS Neurosciences' Alzheimer's Drug PMN310 Shows Early Safety Promise in Phase 1b Trial — ProMIS Neurosciences Inc.

Event summary

ProMIS Neurosciences reported positive blinded six-month interim safety data for PMN310 in the PRECISE-AD Phase 1b trial, showing no ARIA-E across all genotypes.
Early biomarker movement suggests potential target engagement, with 68.5% of patients showing a decline in plasma pTau217 and 62.5% in CSF MTBR-tau243.
Topline 12-month results are expected in Q1 2027, which will include efficacy data.
The trial enrolled 144 participants with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease.

The big picture

ProMIS Neurosciences' PMN310 is designed to selectively target toxic amyloid-beta oligomers, potentially avoiding the ARIA risks associated with other amyloid-directed therapies. The positive interim safety data and early biomarker trends position PMN310 as a promising candidate in the competitive Alzheimer’s disease treatment landscape, where addressing both efficacy and safety remains a critical challenge.

What we're watching

Safety Profile: Whether PMN310 can maintain its favorable safety profile, particularly in high-risk APOE4 carriers, through the 12-month topline results.
Biomarker Validation: How the early biomarker movement translates into clinical efficacy once the trial is unblinded and full data are available.
Regulatory Pathway: The pace at which ProMIS can advance PMN310 through subsequent trials, given its Fast Track Designation from the FDA.